## Edgar Filing: McCracken Joseph S - Form 4

McCracken Form 4	Joseph S										
April 24, 20	ЛЛ								PPROVAL		
	UNITED	STATES					GE COMMISSIO	N OMB Number:	3235-0287		
Washington, D.C. 20549								Expires:	January 31,		
if no longer subject to Section 16. Form 4 or Form 5 Eiled pursuant to Section 16(a) of the Securities							OWNERSHIP OF Estimated average burden hours per response 0.5				
obligatio may con <i>See</i> Instr 1(b).	tinue. Section 17	(a) of the	Public U		ding Cor	npany A	nange Act of 1934, ct of 1935 or Secti f 1940				
(Print or Type	Responses)										
1. Name and A McCracken	2. Issuer Name <b>and</b> Ticker or Trading Symbol Kindred Biosciences, Inc. [KIN]				5. Relationship of Reporting Person(s) to Issuer						
(Last)	(First) (	Middle)					(Check all applicable)				
C/O KINDRED BIOSCIENCES, 04 INC., 1555 BAYSHORE			(Month/	3. Date of Earliest Transaction (Month/Day/Year) 04/20/2018			XDirector10% Owner Officer (give titleOther (specify below)below)				
				. If Amendment, Date Original iled(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting Person</li> </ul>				
(City)	(State)	(Zip)	Tal	ble I - Non-l	Derivative	Securitie	s Acquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	ed Date, if	3. Transactio Code (Instr. 8)	4. Securit nAcquired Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect		
				Code V			ce				
Reminder: Rep	port on a separate line	e for each cl	ass of sec	curities bene	Perso inform requir	ons who i nation co red to res ays a cur	ly or indirectly. respond to the colle ontained in this forn spond unless the fo rently valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab						or Beneficially Owned le securities)	d			
			0 L E								

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Securities	D

## Edgar Filing: McCracken Joseph S - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired or Dispos (D) (Instr. 3, 4 and 5)	(A) ed of	(Month/Day/	/Year)	(Instr. 3 and	4)	:
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 9.65	04/20/2018		А	41,890		<u>(1)</u>	04/19/2028	Common Stock	41,890	
Repo	rting Ov	vners									
Reporting Owner Name / Address			Relationships								
		Director	10% Ow	ner Offic	er (	Other					
C/O KINI 1555 BAY		CIENCES, INC. GHWAY, SUIT 4010	X								
Signa	tures										

## Signatures

/s/ Joseph	
McCracken	04/24/2018
<u>**</u> Signature of Reporting Person	Date

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option will vest in four quarterly installments following the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S ()